ESMO/X
Jan 23, 2025, 20:46
Tiragolumab plus Atezolizumab and chemotherapy failed to improve OS in non-squamous NSCLC – ESMO
ESMO shared on LinkedIn:
“First-line combination of tiragolumab plus atezolizumab and chemotherapy failed to improve progression-free survival (PFS) and overall survival (OS) compared to standard therapy in patients with locally advanced unresectable or metastatic non-squamous NSCLC, according to the results from the SKYSCRAPER-06 study presented at ESMOImmuno24
Read the full news on ESMO Daily Reporter.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 20, 2025, 02:27
Apr 19, 2025, 22:24
Apr 19, 2025, 22:03
Apr 19, 2025, 21:39
Apr 19, 2025, 21:21
Apr 19, 2025, 21:04
Apr 19, 2025, 20:48
Apr 19, 2025, 20:25
Apr 19, 2025, 19:36
Apr 19, 2025, 19:17